[1] Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID–19: immunity, inflammation and intervention. Nat Rev Immunol. 2020 Apr 28. doi: 10.1038/s41577–020–0311–8.
[2] Englund J, Feuchtinger T, Ljungman P. Viral infections in immunocompromised patients. Biol Blood Marrow Transplant. 2011 Jan;17(1 Suppl):S2–5.
[3] Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y, Bai C, Gao T, Song J, Xia P, Dong J, Zhao J, Wang FS. Pathological findings of COVID–19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020 Apr;8(4):420–422.
[4] Effect of Dexamethasone in Hospitalized Patients with COVID–19: Preliminary Report, Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ, RECOVERY Collaborative Group. medRχiv. doi: https://doi.org/10.1101/2020.06.22.20137273.
[5] David M. G. Halpin, Dave Singh, Ruth M. Hadfield. Inhaled corticosteroids and COVID–19: a systematic review and clinical perspective. European Respiratory Journal 2020; DOI: 10.1183/13993003.01009–2020.
[6] Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID–19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020.
[7] Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020.
[8] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID–19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62.
[9] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
[10] Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, Mitnitski A. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005;173(5):489–95.
[11] Hewitt J, Carter B, McCarthy K, Pearce L, Law J, Wilson FV, Tay HS, McCormack C, Stechman MJ, Moug SJ, Myint PK. Frailty predicts mortality in all emergency surgical admissions regardless of age. An observational study. Age Ageing. 2019;48(3):388–94.
[12] Hewitt J, Carter B, Vilches-Moraga A, Quinn TJ, Braude P, Verduri A, Pearce L, Stechman M, Short R, Price A, Collins J, Bruce E, Einarsson A, Rickard F, Mitchell E, Holloway M, Hesford J, Barlow-Pay F, Clini E, Myint PK, Moug SJ and McCarthy K on behalf of the COPE Study Collaborators* The COPE study: COVID–19 in Older PEople—the influence of frailty on survival. A multi-centre, European observational study. Lancet Public Health (in press).
[13] StataCorp. 2017. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC
[14] R Core Team (2019). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/.
[15] Therneau T (2020). A Package for Survival Analysis in R. R package version 3.1–12, https://CRAN.R-project.org/package = survival.
[16] Alboukadel Kassambara, Marcin Kosinski and Przemyslaw Biecek (2019). survminer: Drawing Survival Curves using ‘ggplot2’. R package version 0.4.6. https://CRAN.R-project.org/package = survminer
[17] Jin JM, Bai P, He W, Wu F, Liu XF, Han DM, Liu S, Yang JK. Gender Differences in Patients With COVID–19: Focus on Severity and Mortality. Front Public Health 2020; 8: 152.
[18] Harpaz R, Dahl RM, Dooling KL. Prevalence of Immunosuppression Among US Adults, 2013. JAMA. 2016;316(23):2547–2548. doi:10.1001/jama.2016.16477
[19] Patel M, Chen J, Kim S, Garg S, Flannery B, Haddadin X, et al. Analysis of MarketScan data for immunosuppressive conditions and hospitalizations for acute respiratory illness, United States. Emerg Infect Dis. 2020 Aug [date cited–20 May 2020].
[20] Guidance on the management of transplant recipients diagnosed with or suspected of having COVID19. Joint Guideline British Transplant Society and The Renal Association. Updated March 25th 2020. Accessed 8 May 2020. https://bts.org.uk/wp-content/uploads/2020/03/Clinical_management_transplant_recipients.pdf
[21] Carbajo-Lozoya J, Müller MA, Kallies S, Thiel V, Drosten C, von Brunn A. Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV–229E is inhibited by the drug FK506. Virus Research, 2012;165(1):112–117.
[22] Russell B, Moss C, Rigg A, Van Hemelrijck M. COVID–19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting? Ecancermedicalscience. 2020; 14: 1023.
[23] COVID–19 rapid guideline: dermatological conditions treated with drugs affecting the immune response. NICE guideline [NG169] 2020. Accessed 8 May 2020. https://www.nice.org.uk/guidance/ng169
[24] American Academy of Dermatology. Guidance on the use of medications during COVID–19 outbreak. 15th April 2020. Available at https://assets.ctfassets.net/1ny4yoiyrqia/PicgNuD0IpYd9MSOwab47/5e6d85324e7b5aafed45dde0ac4ea21e/Guidance_on_medications_AHTF_approved_April_15.pdf
[25] Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, Labella A, Manson D, C Kubin C, Barr RG, Sobieszczyk ME, Schluger NW. Observational Study of Hydroxychloroquine in Hospitalized Patients With Covid–19. N Engl J Med. 2020 May 7;NEJMoa2012410. doi: 10.1056/NEJMoa2012410. Online ahead of print.
[26] COVID–19 rapid guideline: severe asthma. NICE guideline [NG166]Published date: 03 April 2020. Accessed 20 May 2020.
[27] Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020 Mar 13:e200994. doi: 10.1001/jamainternmed.2020.0994.
[28] Guidance for management of inflammatory bowel disease during the COVID–19 pandemic. British Society of Gastroenterology, last update 20 April 2020. Accessed 20 May 2020. https://www.bsg.org.uk/covid–19-advice/guidance-for-management-of-inflammatory-bowel-disease-during-the-covid–19-pandemic/
[29] Chinese Clinical Guidance for COVID–19 Pneumonia Diagnosis and Treatment (7th edition). Page Views 浏览量: 93881 Updated 发布时间:2020–03–16 12:00:32.
[30] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID–19 in Wuhan, China: a retrospective cohort study [published correction appears in Lancet. 2020 Mar 28;395(10229):1038] [published correction appears in Lancet. 2020 Mar 28;395(10229):1038]. Lancet. 2020;395(10229):1054–1062.
[31] Argenziano MG, Bruce SL, Slater CL, Tiao JR, Baldwin MR, Barr RG, Chang BP, Chau KH, Choi JJ, Gavin N, Goyal P, Mills AM, Patel AA, Romney MS, Safford MM, Schluger NW, Sengupta S, Sobieszczyk ME, Zucker JE, Asadourian PA, Bell FM, Boyd R, Cohen MF, Colquhoun MI, Colville LA, de Jonge JH, Dershowitz LB, Dey SA, Eiseman KA, Girvin ZP, Goni DT, Harb AA, Herzik N, Householder S, Karaaslan LE, Lee H, Lieberman E, Ling A, Lu R, Shou AY, Sisti AC, Snow ZE, Sperring CP, Xiong Y, Zhou HW, Natarajan K, Hripcsak G, Chen R. Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series BMJ 2020; 369 :m1996.